Acid-Stabilized Plasmin as a Novel Direct-Acting Thrombolytic

Production of Plasma Proteins for Therapeutic Use

Volumn , Issue , 2012, Pages 259-271

  Novokhatny, Valery ^a   Rebbeor, James ^b   Scuderi, Philip ^a   Petteway, Stephen ^c  

^a Grifols   (United States)

^b Process Development and Technology Department   (United States)

^c NONE

Author keywords

Acid stabilized plasmin; Clot lysis and PAs; Direct acting thrombolytics; Plasmin in fibrin clot dissolution; Plasmin, efficacy points

Indexed keywords

EID: 84886172928     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118356807.ch18     Document Type: Chapter

References (60)

1. Ponting CP, Marshall JM, Cederholm-Williams SA. (1992) Plasminogen: a structural review. Blood Coagul Fibrinolysis, 3, 605-614.
2. Violand BN, Castellino FJ. (1976) Mechanism of the urokinase-catalyzed activation of human plasminogen. J Biol Chem, 251, 3906-3912.
3. Robbins KC, Summaria L, Hsieh B, Shah RJ. (1967) The peptide chains of human plasmin mechanism of activation of human plasminogen to plasmin. J Biol Chem, 242, 2333-2342.
4. Sottrup-Jensen L, Claeys H, Zajdel M, Petersen TE, Magnusson S. (1978) The primary structure of human plasminogen: isolation of two lysine-binding fragments and one "mini" plasminogen (MW 38000) by elastase-catalyzed specific limited proteolysis. In: Progress chemical fibrinolysis and thrombolysis, vol. 3 (Davidson JF, Rowan RM, Samama MM, Desnoyers PC eds.). Raven Press, New York, pp. 191-209.
5. Wiman B, Wallen P. (1977) The specific interaction between plasminogen and fibrin. A physiological role of the lysine binding site in plasminogen. Thromb Res, 10, 213-222.
6. Lucas MA, Fretto LJ, McKee PA. (1983) The binding of human plasminogen to fibrin and fibrinogen. J Biol Chem, 258, 4249-4256.
7. Wiman B, Lijnen HR, Collen D. (1979) On the specific interaction between the lysine-binding sites in plasmin and complementary sites in alpha 2-antiplasmin and in fibrinogen. Biochim Biophys Acta, 579, 142-154.
8. Wiman B, Collen D. (1978) On the kinetics of the reaction between human antiplasmin and plasmin. Eur J Biochem, 84, 573-578.
9. Henkin J, Marcotte P, Yang HC. (1991) The plasminogenplasmin system. Prog Cardiovasc Dis, 34, 135-164.
10. Lerch PG, Rickli EE, Lergier W, Gillessen D. (1980) Localization of individual lysine-binding regions in human plasminogen and investigations on their complex-forming properties. Eur J Biochem, 107, 7-13.
11. Wu HL, Chang BI, Wu DH, Chang LC, Gong CC, Lou KL, Shi GY. (1990) Interaction of plasminogen and fibrin in plasminogen activation. J Biol Chem, 265, 19658-19664.
12. Moroi, M, Aoki, N. (1976) Isolation and characterization of alpha 2-plasmin inhibitor from human plasma. A novel proteinase inhibitor which inhibits activator-induced clot lysis. J Biol Chem, 251, 5956-5965.
13. Collen D. (1976) Identification and some properties of a new fast-reacting plasmin inhibitor in human plasma. Eur J Biochem, 69, 209-216.
14. Anonick PK, Wolf BB, Gonias SL. (1990) Regulation of plasmin, miniplasmin, and streptokinase-plasmin complex by alpha 2-antiplasmin, alpha 2-macroglobulin, and antithrombin III in the presence of heparin. Thromb Res, 59, 449-462.
15. Steiner JP, Migliorini M, Strickland DK. (1987) Characterization of the reaction of plasmin with alpha 2-macroglobulin: effect of antifibrinolytic agents. Biochemistry, 26, 8487-8495.
16. Rifkin DB, Gleizes PE, Harpel J, Nunes I, Munger J, Mazzieri R, Noguera I. (1997) plasminogen/plasminogen activator and growth factor activation. Ciba Found Symp, 212, 105-115.
17. Singer AJ, Clark RA. (1999) Cutaneous wound healing. New Engl J of Med, 34, 738-746.
18. Li F, Goncalves J, Faughnan K, Steiner MG, Pagan-Charry I, Esposito D, Chin B, Providence KM, Higgins PJ, Staiano-Coico L. (2000) Targeted inhibition of wound-induced PAI-1 expression alters migration and differentiation in human epidermal keratinocytes. Exp Cell Res, 258, 245-253.
19. Carmeliet P, Collen D. (1995) Gene targeting and gene transfer studies of the biological role of the plasminogen/plasmin system. Thromb Haemost, 74, 429-436.
20. Tillett WS, Garner RL. (1933) The fibrinolytic activity of hemolytic streptococci. Exp Med, 58, 485-502.
21. Milstone H. (1941) Factor in normal blood which participates in streptococcal fibrinolysis. J Immunol, 42, 109-116.
22. Kaplan MH. (1944) Nature and role of the lytic factor in hemolytic streptococcal fibrinolysis. Proc Soc Exp Biol Med, 57, 40-43.
23. Christensen LR. (1945) Streptococcal fibrinolysis: proteolytic reaction due to serum enzyme activated by streptococcal fibrinolysin. J Gen Physiol, 28, 363-383.
24. Christensen LR, Macleod CM. (1945) A proteolytic enzyme of serum: characterization, activation, and reaction with inhibitors. J Gen Physiol, 28, 559-583.
25. Ambrus JL, Ambrus CM, Back N, Sokal JE, Collins GL. (1957) Clinical and experimental studies on fibrinolytic enzymes. Ann NY Acad Sci, 68, 97-136.
26. Clifton EE. (1958) The use of plasmin in the treatment of intravascular thromboses. Am Geriatr Soc J, 6, 118-128.
27. Larsen V, Amris CJ, Brockner J, Storm O. (1966) Fibrinolytic treatment with activator-free porcine plasmin. Scand J Clin Invest, 18, 34-43.
28. Herndon RM, Meyer JS, Johnson IF, Landers J. (1960) Treatment of cerebrovascular thrombosis with fibrinolysin. Am J Cardiol, 6, 540-545.
29. Alkjaersig N, Fletcher AP, Sherry S. (1959) The mechanism of clot dissolution by plasmin. J Clin Invest, 38, 1086-1095.
30. Verstraete M, Amery A, Vermylen J. (1964) Enzymatic clot dissolution in man: a new therapeutic approach. Acta Clin Belg, 19, 271-290.
31. Moser KM. (1959) Effect of intravenous administration of fibrinolysin (plasmin) in man. Circulation, 20, 42-55.
32. Clifton EE. (1960) Review of clinical experience with clotlysing agents. Am J Cardiol, 6, 476-486.
33. Davis ND, Carroll BJ, Schwartz SH. (1960) Treatment of thrombophlebitis with a fibrinolytic agent, with special references to side effects. Am J Cardiol, 6, 513-518.
34. Jensen VJ., inventor; Novo Terapeutisk Labor As, assignee. Improvements in or relating to plasmin preparations. UK patent 985, 498. Mar 10, 1965.
35. Reich E, Easton TG., inventors; Orion Therapeutic Systems, assignee. Fibrinolysis and fibrinogenolysis treatment. US Patent 5, 288, 489. Feb 22, 1994.
36. Gottlob R. (1975) Plasminogen and plasma inhibitors in arterial and venous thrombi of various ages. In: Progress in chemical fibrinolysis and thrombolysis. vol. 1 (Davidson JF, Rowan RM, Samama MM, Desnoyers PC, eds.). Raven Press, New York, pp. 23-36.
37. Sabovic M, Lijnen HR, Keber D, Collen D. (1989) Effect of retraction on the lysis of human clots with fibrin specific and non-fibrin specific plasminogen activators. Thromb Haemost, 62, 1083-1087.
38. Potter van Loon BJ, Rijken DC, Brommer EJ, van der Maas AP. (1992) The amount of plasminogen, tissue-type plasminogen activator and plasminogen activator inhibitor type 1 in human thrombi and the relation to ex-vivo lysibility. Thromb Haemost, 67, 101-105.
39. Anderle K, Frohlich. (1988) A review of studies with plasminogen concentrates and proposal for further therapeutic strategies with plasminogen concentrates. Haemostasis, 18 (Suppl 1), 165-175.
40. Takada Y, Takada A. (1990) The mechanisms of the activation of plasminogen by streptokinase and urokinase. Adv Exp Med Biol, 281, 223-234.
41. Suenson E, Thorsen S. (1981) Secondary-site binding of Gluplasmin, Lys-plasmin and miniplasmin to fibrin. Biochem J, 197, 619-628.
42. Badylak SF, Voytik SL, Henkin J, Burke S, Sasahara AA, Simmons A. (1991) The beneficial effect of lys-plasminogen upon the thrombolytic efficacy of urokinase in a dog model of peripheral arterial thrombosis. Haemostasis, 21, 278-285.
43. Mehta JL, Chen L, Nichols WW, Johannesen M, Bregengard C, Hedner U, Saldeen TG. (1995) Recombinant Lys-plasminogen, but not Glu-plasminogen, improves recombinant tissuetype plasminogen activator-induced coronary thrombolysis in dogs. J Am Coll Cardiol, 25, 753-760.
44. Freitag HJ, Becker VU, Thie A, Tilsner V, Philapitsch A, Schwarz HP, Webhof U, Muller A, Zeumer H. (1996) Lysplasminogen as an adjunct to local intra-arterial fibrinolysis for carotid territory stroke: laboratory and clinical findings. Neuroradiology, 38, 181-185.
45. Novokhatny VV, Jesmok GJ, Landskroner KA, Taylor KK, Zimmerman TP., inventors; Bayer Corporation, assignee. Method of thrombolysis by local delivery of active plasmin. US Patent 6, 355, 243. Mar 12, 2002.
46. Zimmerman TP, Novokhatny V, Landskroner KA, Jesmok GJ, Taylor KK., inventors; Talecris Biotherapeutics, assignee. Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin. US Patent 6, 964, 764. Nov 15, 2005.
47. Marder VJ, Landskroner K, Novokhatny V, Zimmerman TP, Kong M, Kanouse JJ, Jesmok G. (2001) Plasmin induces local thrombolysis without causing haemorrhage: a comparison with tissue plasminogen activator in the rabbit. Thromb Haemost, 86, 739-745.
48. Bradley RT, Cook SA, Dadd CA, Kent JD, Korneyeva MN, Novokhatny VV, Rebbeor JF, Stenland CJ, Strauss JS, Terry JC, Yuziuk JA., inventors; Talecris Biotherapeutics, assignee. Process for the production of a reversibly inactive acidified plasmin composition. US Patent 7, 544, 500. Jun 9, 2009.
49. Puskas M, Fredlin J, Woznichak M, Vandeberg P. (2007) Characterization of a reduced capillary electrophoresis method for the measurement of autolysis of the plasma derived protein, plasmin. The AAPS Journal, 9, S2.
50. Novokhatny V, Taylor K, Zimmerman TP. (2003) Thrombolytic potency of acid-stabilized plasmin: superiority over tissue-type plasminogen activator in an in vitro model of catheterassisted thrombolysis. J Thromb Haemost, 1, 1034-1041.
51. Landskroner K, Olson N, Jesmok G. (2005) Cross-species pharmacologic evaluation of plasmin as a direct-acting thrombolytic agent: ex vivo evaluation for large animal model development. J Vasc Interv Radiol, 16, 369-377.
52. Jahan R, Stewart D, Vinters HV, YongW, Vinuela F, Vandeberg P, Marder VJ. (2008) Middle cerebral artery occlusion in the rabbit using selective angiography: application for assessment of thrombolysis. Stroke, 39, 1613-1615.
53. Marder VJ, Jahan R, Gruber T, Goyal A, Arora V. (2010) Thrombolysis with plasmin: implications for stroke treatment. Stroke, 41, (10 Suppl), S45-S49.
54. Stewart D, Kong M, Novokhatny V, Jesmok G, Marder VJ. (2003) Distinct dose-dependent effects of plasmin and tPA on coagulation and haemorrhage. Blood, 101, 3002-3007.
55. Arora V, Baumbach GA, Scuderi P, Petteway SR. (2009) Preclinical toxicology and safety pharmacology of plasmin (Human). J ThrombHeamost, 7, 1066.
56. Shlansky-Goldberg RD, Matsumoto AH, Baumbach GA, Siegel JB, Raabe RD, Murphy TP, Deng C, Ray Dawkins J, Marder VJ. (2008) A first-in-human phase I trial of locally delivered human plasmin for hemodialysis graft occlusion. J Thromb Haemost, 6, 944-950.
57. Shlansky-Goldberg R. (2008) Phase 1 study of human plasmaderived plasmin (TAL-05-00018) in hemodialysis graft occlusion. Thromb Res, 122, (Suppl 3), S16-S19.
58. Comerota AJ. (2008) Development of catheter-directed intrathrombus thrombolysis with plasmin for the treatment of acute lower extremity arterial occlusion. Thromb Res, 122, (Suppl 3), S20-S26.
59. Comerota AJ, Fineberg D, Shlansky-Goldberg R, Deng C, Marder VJ. (2011) Plasmin (human) TAL-05-00018 demonstrated a good safety profile in patients with acute peripheral arterial occlusion. J Vascular Surg, 53, (6), 62S.
60. National Institutes of Health, USA (clinicaltrials.gov). (2011) Safety and dose finding study of plasmin (human) administered into the middle cerebral artery of stroke patientsNCT01014975. h ttp://clinicaltrials.gov/ct2/s how/NCT01 0149 75?term1/4plasmin &rank1/42. Aceessed November 18, 2011.